Thelansis’s “Major Depressive Disorder (MDD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Major depressive disorder (MDD) is a severe, highly prevalent mood disorder driven by complex neurobiological interactions involving monoaminergic depletion, HPA axis dysregulation, altered neuroplasticity, and glutamatergic dysfunction. Patients present with at least two weeks of pervasive sadness, anhedonia, cognitive impairment, neurovegetative symptoms (sleep and appetite disturbances), and potential suicidality. Diagnosis strictly relies on DSM-5 criteria, requiring the exclusion of bipolar disorder and secondary medical etiologies. Management typically begins with cognitive behavioral therapy and traditional oral monoaminergic antidepressants (SSRIs, SNRIs, bupropion). However, because up to a third of patients develop treatment-resistant depression (TRD), the therapeutic landscape has rapidly evolved beyond classic serotonin modulation. Rapid-acting glutamatergic agents, specifically intranasal esketamine, alongside the oral NMDA receptor antagonist combination dextromethorphan/bupropion, now provide critical interventions for TRD and acute suicidal ideation. Furthermore, GABAergic modulation via oral zuranolone delivers rapid, episodic symptom resolution. For severe, refractory cases, neuromodulation (transcranial magnetic stimulation, electroconvulsive therapy) remains an essential standard of care.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Major Depressive Disorder (MDD) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report
Our team will get in touch with you shortly about the Major Depressive Disorder (MDD) – Epidemiology Insights and Disease Burden Report – 2020 To 2040 report.